Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation titled “Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer: Results From the Randomized Clinical Trials of Alendronate and Zoledronic Acid” published in the October 2014 issue of JAMA Internal Medicine (2014;174:1551-1558. doi:10.1001/jamainternmed.2014.3634), there was an error in the Conflict of Interest Disclosures.
The correct version reads as follows: “Dr Ensrud serves as a consultant on a data monitoring committee for Merck Sharp & Dohme. Dr Black has received grant support from Novartis and Merck and consulting, lecture, or advisory board fees from Lilly, Novartis, Amgen, Radius, and Merck. No other disclosures are reported.” This article was corrected online.
Missing Conflict of Interest Disclosure. JAMA Intern Med. 2014;174(11):1875. doi:10.1001/jamainternmed.2014.5554